BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNYSEAMERICAN:BTX
Previous SymbolNYSEMKT:BTX
CUSIP09066L10
Phone+1-510-5213390
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees92
Outstanding Shares126,960,000
Market Cap$0.00
OptionableOptionable
BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions
What is BioTime's stock symbol?
BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."
How were BioTime's earnings last quarter?
BioTime, Inc. (NYSEAMERICAN:BTX) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The biotechnology company had revenue of $0.98 million for the quarter, compared to analyst estimates of $0.75 million. View BioTime's Earnings History.
When is BioTime's next earnings date?
What price target have analysts set for BTX?
1 equities research analysts have issued 1-year price targets for BioTime's shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate BioTime's stock price to reach $8.00 in the next year. This suggests a possible upside of 373.4% from the stock's current price. View Analyst Price Targets for BioTime.
What is the consensus analysts' recommendation for BioTime?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime.
Has BioTime been receiving favorable news coverage?
News coverage about BTX stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioTime earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
Are investors shorting BioTime?
BioTime saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 14,481,443 shares, an increase of 2.0% from the October 15th total of 14,198,940 shares. Based on an average daily volume of 341,212 shares, the short-interest ratio is presently 42.4 days. Currently, 11.5% of the company's stock are short sold. View BioTime's Current Options Chain.
Who are some of BioTime's key competitors?
Some companies that are related to BioTime include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are BioTime's key executives?
BioTime's management team includes the folowing people:
- Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
- Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 47)
- Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 64)
- Mr. Brian M. Culley, CEO , Pres & Director (Age 47)
- Mr. David Nakasone, Director of Investor Relations
Who are BioTime's major shareholders?
BioTime's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.81%), AXA (1.66%), IndexIQ Advisors LLC (0.67%), Destination Wealth Management (0.41%), TIAA CREF Investment Management LLC (0.28%) and Morgan Stanley (0.16%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.
Which major investors are selling BioTime stock?
Which major investors are buying BioTime stock?
BTX stock was acquired by a variety of institutional investors in the last quarter, including Destination Wealth Management, BlackRock Inc., Bridgeway Capital Management Inc., Jefferies Group LLC, IndexIQ Advisors LLC and Teachers Advisors LLC. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.
How do I buy shares of BioTime?
Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioTime's stock price today?
One share of BTX stock can currently be purchased for approximately $1.69.
What is BioTime's official website?
How can I contact BioTime?
BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.
MarketBeat Community Rating for BioTime (NYSEAMERICAN BTX)
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
